AW ACTAVIS - Trademark Details
Status: 734 - Fifth Extension - Granted
Serial Number
87837595
Word Mark
AW ACTAVIS
Status
734 - Fifth Extension - Granted
Status Date
2021-11-16
Filing Date
2018-03-16
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s)
Typeset
Design Searches
261121 - Rectangles that are completely or partially shaded.
Published for Opposition Date
2019-03-19
Attorney Name
Law Office Assigned Location Code
N30
Employee Name
BLACK, MILDRED ELIZABE
Statements
Indication of Colors claimed
The color(s) gray and white is/are claimed as a feature of the mark.
Description of Mark
The mark consists of the word "ACTAVIS" below the letters "A" and "W", which appear in an intertwined fanciful lettering style that resembles a horizontal zig-zag line or a coil, which are both displayed in the color white. The word "ACTAVIS" and the letters "A" and "W" are centered within a rectangle displayed in the color gray.
Goods and Services
Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, neurological disorders, neurodegenerative disorders, and depression, antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic, anti-inflammatory ointments; ocular wetting solutions, artificial tears and formulations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2018-03-23
Primary Code
005
Current Trademark Owners
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Correspondences
Name
Laurence Rickles
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship Type | Reel Number |
Prior Registration | 4673382 |
Prior Registration | 4686249 |
Prior Registration | 4686257 |
Trademark Events
Event Date | Event Description |
2018-03-20 | NEW APPLICATION ENTERED IN TRAM |
2018-03-23 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2018-03-24 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
2018-06-27 | ASSIGNED TO EXAMINER |
2018-07-09 | NON-FINAL ACTION WRITTEN |
2018-07-09 | NON-FINAL ACTION E-MAILED |
2018-07-09 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2019-01-09 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2019-01-09 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2019-01-09 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2019-01-26 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2019-02-11 | ASSIGNED TO LIE |
2019-02-27 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2019-03-19 | PUBLISHED FOR OPPOSITION |
2019-03-19 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2019-05-14 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2019-07-11 | TEAS EXTENSION RECEIVED |
2019-07-11 | EXTENSION 1 FILED |
2019-07-11 | EXTENSION 1 GRANTED |
2019-07-13 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2020-05-12 | TEAS EXTENSION RECEIVED |
2020-05-12 | EXTENSION 2 FILED |
2020-05-12 | EXTENSION 2 GRANTED |
2020-05-14 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2020-11-05 | TEAS EXTENSION RECEIVED |
2020-11-05 | EXTENSION 3 FILED |
2020-11-05 | EXTENSION 3 GRANTED |
2020-11-07 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-05-14 | TEAS EXTENSION RECEIVED |
2021-05-14 | EXTENSION 4 FILED |
2021-05-14 | EXTENSION 4 GRANTED |
2021-05-18 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-11-09 | TEAS EXTENSION RECEIVED |
2021-11-16 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2021-11-09 | EXTENSION 5 FILED |
2021-11-16 | EXTENSION 5 GRANTED |
2021-11-17 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |